BioStock: Cereno Scientific to present promising CS585 data

Cereno Scientific has been awarded acceptance of an abstract for an oral presentation at the European Hematology Association 2022 Hybrid Congress. At the conference, Cereno will show promising data pertaining to newly-nominated preclinical candidate CS585 and its ability to prevent thrombosis without increasing the risk of bleeding, a significant unmet need in the current market.

Read the article at biostock.se:

https://www.biostock.se/en/2022/05/cereno-scientific-presenterar-lovande-cs585-data/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/en/